Tempus AI, Predicta Expand Genomics Test for Blood Cancer
Chicago, Illinois, U.S. | April 15, 2026 Tempus AI, Inc., in collaboration with Predicta Biosciences, has announced the expansion...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Chicago, Illinois, U.S. | April 15, 2026 Tempus AI, Inc., in collaboration with Predicta Biosciences, has announced the expansion...
IRVING, Texas, USA, March 31, 2026 Caris Life Sciences has announced final results from the Achieve 1 study, demonstrating...
IRVING, Texas, February 26, 2026 Caris Life Sciences® (NASDAQ: CAI) announced an interim readout from its Achieve 1 clinical...
Dateline – Silver Spring, MD, September 18, 2025 – The U.S. Food and Drug Administration (FDA), in coordination with...
